Key facts
- Auxilium Biotechnologies’s last known valuation is $92.7M (Dec 2025).
- It has raised $7.2M across 2 recorded rounds; the latest was Seed Round ($3.9M) in Sep 2025.
- Notable investors include University of California, Innovation Partnerships, CF Ventures, San Diego.
- Auxilium Biotechnologies has filed 2 Form Ds with the SEC since 2020, most recently Dec 2025 ($3.9M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Auxilium Biotechnologies
Funding rounds
2 roundsAbout Auxilium Biotechnologies
Operator of a biotechnology company intended to help treat traumatic injuries of the nervous system. The company focuses on innovation and collaboration, and develops cutting-edge bioprinting products and implantable medical devices, enabling people to get proper nerve treatment.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Website
- auxiliumbio.com/
- Ownership
- Privately Held (backing)
Auxilium Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Auxilium Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Auxilium Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.